Demographics were also different in the two trials with the SELECT trial containing an older, less female dominant, on average lower starting BMI and more comorbid population
Making these changes can often help people control pain while staying on track with their weight management goals
In August 2025, Wegovy received accelerated approval for the treatment of adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver
Healthcare providers can evaluate treatment plans, suggest lifestyle modifications, and recommend appropriate adjustments when necessary
While slower gut motility is a well-established risk factor for bacterial overgrowth, it does not guarantee that you will develop SIBO, IMO, or related conditions